locked nucleic acid

oligonucleotide that contains one or more LNA monomer (2'-O,4'-C-methylene-beta-D-ribofuranosyl monomer); has an exceptionally high affinity and specificity toward their complementary DNA and RNA target molecules, used in functional genomics applications; structure in first source

Also Known As:

Networked: 117 relevant articles (9 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kauppinen, Sakari: 6 articles (12/2013 - 02/2006)
2.	Obad, Susanna: 4 articles (02/2014 - 08/2012)
3.	Tanaka, Tomoaki: 4 articles (02/2013 - 08/2005)
4.	Hagiwara, Koichi: 4 articles (02/2013 - 08/2005)
5.	Kanwar, Jagat R: 3 articles (09/2015 - 06/2012)
6.	Salehi, Rasoul: 3 articles (05/2014 - 06/2013)
7.	Gheisari, Yousof: 3 articles (05/2014 - 06/2013)
8.	Kazemi, Mohammad: 3 articles (05/2014 - 06/2013)
9.	Sharifi, Mohammadreza: 3 articles (05/2014 - 06/2013)
10.	Pession, Annalisa: 3 articles (03/2014 - 01/2010)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2005 - "Both alpha-L-LNA and LNA gapmer ODNs had a high efficacy of tumor-growth inhibition and were nontoxic at the tested dosages. " 01/01/2008 - "Locked nucleic acid holds promise in the treatment of cancer." 01/01/2004 - "A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis." 12/01/2015 - "MiR-483-3p levels were evaluated by locked nucleic acid-in situ hybridization (LNA-ISH) in a tissue microarray including 63 PDAC tumors and 10 normal pancreatic tissues, followed by evaluation in an independent set of 117 pairs of matched PDAC tumors and adjacent tumor-free pancreatic tissues. " 01/01/2014 - "miR-205 expression was investigated in 48 cases of inflammatory, benign and malignant tumor tissue array of the neck, oronasopharynx, larynx and salivary glands by Locked Nucleic Acid in situ hybridization (LNA-ISH) technology. "
2.	Infection 11/01/2013 - "Two fluorescent, locked nucleic acid probes ShaemLNA5 and SmanLNA2, of 20-26bp in length, were identified and found to be effective in providing evidence of infection in field-collected snails. " 06/01/2014 - "Our findings showed that bmnpv-miR-3 expresses during early stage of infection, and negatively regulates the expression of P6.9. There was an upregulation in P6.9 expression upon blocking of bmnpv-miR-3 by Locked Nucleic Acid (LNA), whereas overexpression of bmnpv-miR-3 resulted in a decreased expression of P6.9. Besides, a remarkable enhancement and reduction in the viral loads were observed upon blocking and overexpression of bmnpv-miR-3, respectively. " 03/22/2011 - "Recently, it was demonstrated that locked nucleic acid SPC3649-induced miR-122 antagonism suppressed HCV genotype 1a and 1b infection in vivo. " 04/01/2009 - "We have developed a broad-range real-time PCR assay using the locked nucleic acid technology to detect mollicute species causing human infection and cell line contamination. " 01/01/2013 - "We show further that vp28-siRNA predominates in the cytoplasm of shrimp hemocytes at 48 h p.i. Knockdown of Dicer2 by special siRNA or inhibition of vp28-siRNA with locked nucleic acid antisense oligonucleotides both lead to a significant increase in WSSV copy number at 24-48 h p.i. Our study highlights a novel aspect of the siRNA pathway in the immune response of animals against infection by DNA viruses."
3.	Breast Neoplasms (Breast Cancer) 12/07/2014 - "Locked nucleic acid (LNA) is applied in toehold-mediated strand displacement reaction (TMSDR) to develop a junction-probe electrochemiluminescence (ECL) biosensor for single-nucleotide polymorphism (SNP) detection in the BRCA1 gene related to breast cancer. " 12/01/2010 - "The future application of locked-nucleic acid miRNA inhibitors, and synergistic approaches involving conventional breast cancer therapeutics opens up promising new perspectives in breast cancer therapy." 08/15/2013 - "miRNA from paired breast cancer tumors, normal tissue, and serum samples derived from 32 patients were comprehensively profiled using microarrays or locked nucleic acid real-time PCR panels. " 06/11/2015 - "In this study, we investigated the efficacy of an LNA (locked nucleic acid)-modified DNA aptamer named RNV66 targeting VEGF against various breast cancer cell lines. "
4.	Prostatic Neoplasms (Prostate Cancer) 01/01/2007 - "We have investigated the effects of different locked nucleic acid modified antisense mRNA antagonists against Survivin in a prostate cancer model. " 11/12/2013 - "First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer." 06/01/2010 - "This conference report highlights selected presentations on the development of the third-generation camptothecin analog TH-1320 (Threshold Pharmaceuticals Inc), the silencing of the androgen receptor in prostate cancer by the novel locked nucleic acid-based antisense oligonucleotide EZN-4176 (Enzon Pharmaceuticals Inc/Santaris Pharma A/S), the inhibition of PC-3 cell invasiveness and metastasis by the CXCR4 antagonist CTCE-9908 (British Canadian BioSciences Corp), the antitumor efficacy of the CDH3 mAb PPMX-2017 (Perseus Proteomics Inc), and an anti-IL-6 mAb (MedImmune LLC) that suppresses tumor growth in vivo."
5.	Neoplasm Metastasis (Metastasis) 04/01/2014 - "Silencing of miR-133a with locked nucleic acid (LNA) reduced cell invasion of this cell population, and systemic administration of LNA along with chemotherapy suppressed lung metastasis and prolonged the survival of osteosarcoma-bearing mice. " 06/01/2010 - "This conference report highlights selected presentations on the development of the third-generation camptothecin analog TH-1320 (Threshold Pharmaceuticals Inc), the silencing of the androgen receptor in prostate cancer by the novel locked nucleic acid-based antisense oligonucleotide EZN-4176 (Enzon Pharmaceuticals Inc/Santaris Pharma A/S), the inhibition of PC-3 cell invasiveness and metastasis by the CXCR4 antagonist CTCE-9908 (British Canadian BioSciences Corp), the antitumor efficacy of the CDH3 mAb PPMX-2017 (Perseus Proteomics Inc), and an anti-IL-6 mAb (MedImmune LLC) that suppresses tumor growth in vivo."

Related Drugs and Biologics

1.	DNA (Deoxyribonucleic Acid)
2.	Androgen Receptors (Androgen Receptor)
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
4.	Camptothecin
5.	Angiotensin II
6.	CTCE-9908
7.	MicroRNAs (MicroRNA)
8.	Oligonucleotides
9.	Antisense Oligonucleotides
10.	Epidermal Growth Factor Receptor (EGF Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Castration
3.	Drug Therapy (Chemotherapy)
4.	Stem Cell Transplantation
5.	Intraperitoneal Injections